Nivolumab Plus Carboplatin and Paclitaxel as the First-Line Therapy for Advanced Squamous Cell Carcinoma of the Lung With Strong Programmed Death-Ligand 1 Expression: A Case Report

Cureus
doi 10.7759/cureus.5881
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cureus, Inc.

Related search

A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel as First-Line Therapy for Patients With Advanced Non-Small-Cell Lung Cancers

Archives of Medical Science
Medicine
2014English

JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.16-08 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The Expression of Programmed Death Ligand-1 Within Stages of Oral Squamous Cell Carcinoma: Immunohistochemical Analysis

Journal of Advances in Medicine and Medical Research
2020English

Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?

Cancer
Cancer ResearchOncology
2017English

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2014English

Programmed Death-Ligand 1 Expression Correlates With Diminished CD8+ T Cell Infiltration and Predicts Poor Prognosis in Anal Squamous Cell Carcinoma Patients

Cancer Management and Research
Oncology
2017English

Inflammation Promotes Oral Squamous Carcinoma Immune Evasion via Induced Programmed Death Ligand‑1 Surface Expression

Oncology Letters
Cancer ResearchOncology
2013English

A Phase Ib/Ii Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel as First-Line Treatment in Patients With Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

ESMO Open
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy